Abstract
Inhibitory synapses play key roles in the modulatory circuitry that regulates pain signaling and generation of migraine headache. A rare, dominant form of this common disease, familial hemiplegic migraine type 1 (FHM1), arises from missense mutations in the pore-forming α1A subunit of P/Q-type Ca2+ channels. These channels are normally vital for presynaptic Ca2+ entry and neurotransmitter release at many central synapses, raising questions about effects of FHM1 mutations on neuronal Ca2+ influx and inhibitory and excitatory neurotransmission. We have expressed the four original FHM1 mutant channels in hippocampal neurons from α1A knockout mice. Whole-cell recordings indicated that FHM1 mutant channels were less effective than wild-type channels in their ability to conduct P/Q-type current, but not generally different from wild type in voltage-dependent channel gating. Ca2+ influx triggered by action potential waveforms was also diminished. In keeping with decreased channel activity, FHM1 mutant channels were correspondingly impaired in supporting the P/Q-type component of inhibitory neurotransmission. When expressed in wild-type inhibitory neurons, FHM1 mutant channels reduced the contribution of P/Q-type channels to GABAergic synaptic currents, consistent with a competition of mutant and endogenous channels for P/Q-specific slots. In all cases, N-type channels took up the burden of supporting transmission and homeostatic mechanisms maintained overall synaptic strength. The shift to reliance on N-type channels greatly increased the susceptibility to G protein-coupled modulation of neurotransmission, studied with the GABAB agonist baclofen. Thus, mutant-expressing synapses might be weakened in a heightened state of neuromodulation like that provoked by triggers of migraine such as stress.
Keywords: action potential waveform, inhibitory hippocampal neuron
Migraine, the most common neurological disease (1, 2), can be associated with subclinical deficiencies in synaptic transmission in certain migraineurs (3). The hypothesis that migraine may be a synaptic disease has gained further credence through pioneering studies of familial hemiplegic migraine type 1 (FHM1), a rare hereditary form of migraine, and the identification of mutations in a neuronal Ca2+ channel vital for neurotransmission (4). The affected CACNA1A gene encodes the pore-forming α1A subunit of the P/Q-type channel (CaV2.1), a predominant mediator of voltage-gated Ca2+ entry and transmitter release at many synapses in the central nervous system (5–9). Alterations in synaptic signaling are of likely importance for cross-talk between an ascending pain transmission pathway and inhibition by a powerful descending modulatory system, interactions that ultimately govern the generation of headache pain (10, 11). Despite extensive study of the role of P/Q-type channels in pain circuits (12, 13) and the impact of FHM1 mutations on P/Q-type channels (14–20), several important questions have not yet been addressed. What are the effects of FHM1 mutations on inhibitory neurotransmission and how might they be related to changes in biophysical properties of the P/Q-type channel and action potential-triggered Ca2+ entry? Do FHM1-related changes in P/Q-type channels alter the contributions of other neuronal Ca2+ channels? Do such alterations influence the way that synaptic transmission might be modulated, pertinent to neurohormonal states that favor the triggering of migraine? Answering these questions would help provide a foundation for a bottom-up approach to the pathophysiology of FHM1.
Materials and Methods
Human α1A Constructs. The wild-type human (WT) human α1A cDNA used in this study encodes the BI-1 (V1) splice variant (21). Individual FHM1 mutations were generated by PCR mutagenesis (Stratagene) as described (18).
Cell Culture and Transfection. Wild-type (α1A+/+) and α1A knockout (α1A-/-) pups were generated by heterozygote crosses in accordance with the guidelines of the Animal Care and Use Committee of Stanford University. Hippocampal neurons were cultured from 1-day-old pups as described (18). Individual human α1A constructs were cotransfected with pEGFPC1 plasmid (1:1 molar ratio) into 5-days in vitro (DIV) cultures by using a calcium phosphate method (18).
Electrophysiology. Transfected neurons were identified by EGFP fluorescence under an inverted microscope. Whole-cell patch-clamp recordings were performed at room temperature with an Axopatch 200A amplifier (Axon Instruments, Union City, CA). pclamp 8.2 (Axon Instruments) was used to acquire and analyze data. Signals were filtered at 1 kHz and digitized at 10 kHz. Whole-cell Ba2+ current and synaptic current recordings were performed as described (18). Details of solution composition and drug application are provided in Supporting Text, which is published as supporting information on the PNAS web site.
Ba2+ Current Recording. Transfected neurons were recorded between 7 and 11 DIV, with 10 mM Ba2+ in the extracellular solution. Neurons were voltage-clamped at -80 mV and test pulses were applied every 10 s. For each neuron, the peak current was normalized by the membrane capacitance (a measure of cell surface area) to reflect current density.
Generation of Action Potential Waveform (APW) and Ca2+ Current Recording. Spontaneous action potentials in hippocampal neurons were recorded under whole-cell current-clamp mode and modified in shape to have a faster rising phase to mimic action potentials at presynaptic terminals (see Fig. 3A). This APW was used as a command signal to elicit Ca2+ influx through voltage-gated Ca2+ channels (4 mM external Ca2+). All other recording conditions were the same as in Ba2+ current recordings.
Excitatory and Inhibitory Synaptic Transmission. Recordings were made from transfected low-density cultures (∼5,000 cells per coverslip) between 12 and 18 DIV. The recording chamber was perfused with Tyrode solution (0.5 ml/min) containing 4 mM CaCl2 or MgCl2. A nonfluorescent neuron in close proximity to the transfected, EGFP-positive neuron was chosen as its possible postsynaptic target. Both neurons were voltage-clamped at -70 mV. The transfected, presynaptic neuron was depolarized to 0 mV for 1 ms to elicit action potentials once every 10 s. Correspondingly, an excitatory postsynaptic current (EPSC) or inhibitory postsynaptic current (IPSC) could be recorded at the untransfected, postsynaptic neuron. Peak EPSC/IPSC amplitude under each pharmacological condition was measured as the average of 20 traces. Details of the drug concentration and application procedures are described in Supporting Text.
Statistical Analysis. All data are reported as mean ± SEM. Statistical significance was tested by using ANOVA) with a post hoc Bonferroni test. The nonparametric Kolmogorov–Smirnov test was used to compare IPSC amplitudes between two groups.
Results
Total and P/Q-Mediated Ba2+ Current Densities Were Significantly Reduced in Neurons Expressing FHM1 Mutant Channels. The four original FHM1 mutations described by Ophoff et al. (4) (R192Q, T666M, V714A, and I1811L; RQ, TM, VA, and IL, respectively in Fig. 1A) all resulted in decreased P/Q-type current densities when studied in α1A-/- neurons (17, 18). Because most neurons express multiple types of high voltage-activated (HVA) Ca2+ channels (L-, N-, P/Q-, and R-types) (22), we asked whether other Ca2+ channels undergo regulation to compensate for reduced P/Q current in neurons expressing FHM1 mutants, as occurs in certain α1A-/- cerebellar neurons (23, 24).
Following the same strategy as in our previous study (18), we expressed human WT or FHM1 mutant α1A subunits in cultured α1A-/- hippocampal neurons and measured whole-cell Ca2+ channel currents at 7–11 DIV, using 10 mM Ba2+ as the charge carrier (Fig. 1B). Neurons expressing mutant channels suffered a ∼50% reduction of total Ba2+ current density relative to those expressing WT P/Q-type channels across a broad voltage range (0 to +50 mV). This finding indicated that other Ca2+ channels did not fully make up for the reduction of P/Q-type current in FHM1 mutant-expressing neurons.
To evaluate the current densities supported by individual Ca2+ channel types, we bath-applied type-specific blockers for HVA Ca2+ channels while evoking Ba2+ currents with depolarizing pulses (Fig. 1 C and D Inset). L-, N-, and P/Q-type currents were identified as currents sensitive to nifedipine, ω-conotoxin-GVIA, and ω-agatoxin-IVA (ω-Aga-IVA) (22). The remaining Cd2+-sensitive current was taken as R-type current. Little or no Ba2+ current could be detected after application of 100 μM Cd2+. There was no significant activity of T-type Ca2+ channels under our recording conditions. All four FHM1 mutations resulted in substantial reduction of the P/Q-type current density (Fig. 1D), consistent with our previous study (18). In contrast, L-, N-, and R-type current densities were not significantly different among the neurons expressing WT or FHM1 mutant channels (Fig. 1D). Thus, other HVA Ca2+ channels did not compensate for the deficit in P/Q-type channel activity in whole-cell recordings.
The reduction of overall somatodendritic Ca2+ influx in response to depolarization may have important functional implications. For example, in the Rolling Nagoya mouse, attenuation of P/Q-type current in Purkinje neurons causes deficits in generating Ca2+ spikes and subsequent bursts of Na+ spikes that would be seen in α1A+/+ mice (25). In other neurons, inhibition of N- or P/Q-type Ca2+ channels attenuates Ca2+-dependent afterhyperpolarizations, thereby promoting spike generation (26).
Properties of WT and Mutant P/Q-Type Channels in Hippocampal Neurons. We went on to characterize some key biophysical properties of FHM1 mutant channels, again using ω-Aga-IVA sensitivity to identify P/Q-type current. First, we looked for shifts in voltage dependence of activation. Despite sharp reductions of current density in the mutant channels, the overall shape of the current–voltage relationship did not change appreciably (18). Possible displacements in the voltage dependence of activation were studied in greater detail by analysis of tail currents (Fig. 2A). Tails of P/Q-type current were evoked by repolarizing steps to -80 mV after brief depolarizing steps to various voltage levels. The FHM1 mutants displayed a hint of a small negative shift of the midpoint voltage of the activation curve (V50,tail) but this failed to reach statistical significance by ANOVA (Table 1, which is published as supporting information on the PNAS web site). None of the mutant channels displayed a depolarizing shift; thus, displacements in voltage dependence were not responsible for the overall decrease of current density.
Second, we examined voltage-dependent inactivation in WT and mutant channels with a two-pulse protocol. Three-second prepulses to various potentials were followed by a fixed voltage pulse to +10 mV to elicit Ba2+ influx through the channels that remained available after the prepulse inactivation. The voltage dependence of inactivation followed a typical Boltzmann curve (Fig. 2B). Only the RQ mutant showed a negative shift in midpoint voltage (V50,inact) of ∼15 mV (P < 0.01) and a substantial decrease in steepness (P < 0.05, Table 1). Because the expression levels of WT and mutant α1A are comparable (18), changes in the other aspects of P/Q-type channel biophysical properties may contribute to the deficit caused by FHM1 mutations. Our preliminary experiments on TM mutant indicate that the deficit in whole-cell current can be traced to a loss of gating charge movement in mutant channels, sharply diminishing the abundance of functionally gating channels per unit surface a1A protein (C. F. Barrett, Y.-Q.C., and R.W.T., unpublished data).
Precedent for a deficit in channel activity without overt alterations in the voltage dependence of channel gating or in channel protein levels comes from the ataxic mouse leaner (tgla). A mutation in the C terminus of mouse α1A significantly reduces P/Q-type Ca2+ currents in tgla cerebellar Purkinje cells (27, 28), without detectably lowering of α1A mRNA or protein (29). In mice lacking α-neurexin, a functional weakening of N-type Ca2+ channels is observed despite the normal surface abundance of the channel protein (30).
FHM1 Mutations Reduce Ca2+ Influx Triggered by APWs. Next, we tested whether FHM1 mutations diminished Ca2+ influx under spiking conditions relevant to neurotransmission. Ca2+ channels were activated by an experimentally derived APW (Fig. 3A), not a rectangular pulse, and the permeant ion was Ca2+, not Ba2+. Ion fluxes through Na+ and K+ channels were blocked pharmacologically. The APW command elicited an inward Ca2+ current that peaked during the repolarization phase (31). The inward current surge was diminished by ω-Aga-IVA and nearly eliminated by Cd2+ (Fig. 3A). The peak P/Q-type Ca2+ influx was significantly smaller for RQ and TM than for WT, a reduction averaging >60% (Fig. 3B Right). This difference was clear in running integrals of charge transfer (Fig. 3C), which also showed that the timing of the normalized Ca2+ influx was not different between mutant and WT (Fig. 3D).
FHM1 Ca2+ Channels Are Deficient in Mediating Inhibitory Neurotransmission. The efficiency of neurotransmission depends critically on HVA Ca2+ channels positioned close to vesicular release sites. We have reported that FHM1 mutant channels are impaired in mediating excitatory transmission, in close accord with their deficiency in supporting Ca2+ channel activity (18). Here, we describe the effect of FHM1 mutations on inhibitory neurotransmission. We expressed various α1A constructs in low-density α1A-/- hippocampal cultures and studied transmission from transfected neurons to nearby untransfected neurons with paired patch–clamp recordings at 12–18 DIV. Inhibitory connections constituted ∼20% of the 350 synaptically connected pairs of neurons that we studied. In contrast to EPSCs, the IPSCs were larger, decayed much more slowly, and were completely blocked by 10 μM bicuculline (data not shown).
We defined the relative contributions of N-, P/Q-, and R-type Ca2+ channels to inhibitory transmission with sequential and cumulative application of specific channel blockers (Fig. 4A). Each toxin produced a crisp and maintained reduction in IPSC size. With all three toxins present, no remaining synaptic transmission could be detected, as confirmed by further application of bicuculline (data not shown). The contribution of L-type Ca2+ channels to IPSCs was negligible (data not shown) (32). Inhibitory transmission between α1A-/- neurons (ko group) was predominantly mediated by N-type channels (96 ± 1%, Fig. 4B). At synapses expressing WT human α1A (WT group), N-type channels accounted for ∼30% of the IPSC, whereas ω-Aga-IVA blocked 66 ± 5% of the synaptic transmission, not significantly different (P > 0.15) from that in α1A+/+ neurons (54 ± 7%, see Fig. 6, EGFP group). In either case, blocking R-type channels had little additional effect. Thus, expression of WT human α1A subunits at α1A-/- inhibitory synapses restored the normal contribution of P/Q-type channels to IPSCs (see also ref. 18). In contrast to endogenous mouse or WT human P/Q-type channels, FHM1 mutant channels were handicapped in mediating inhibitory transmission, supporting only 20–30% of the IPSC rather than ∼60%. Instead, N-type channels dominated transmission in nerve terminals expressing mutant channels, just as in α1A-/- synapses. The mutations most sharply reducing Ca2+ channel activity, RQ and TM, also produced the largest reduction in P/Q-dependent GABAergic transmission (Fig. 4B).
Absolute IPSC amplitudes are compared in Fig. 4 C and D. Median amplitudes of P/Q-mediated IPSCs seemed smaller for each of the FHM1 mutants, but this difference only reached statistical significance for TM, the mutation with the largest sample size (n = 11). Only four to six inhibitory presynaptic neurons were obtained for the other mutants, reflecting the small number of inhibitory neurons in hippocampal cultures. To circumvent the paucity of inhibitory connections, we pooled data from all of the FHM1 mutants (n = 26, Fig. 4D) and found a significantly smaller P/Q-mediated component of the IPSC than at WT inhibitory synapses (P < 0.05). All in all, the data in Fig. 4 B–D indicated that FHM1 mutant channels were less capable than WT channels in supporting IPSCs.
GABAB Receptor-Mediated Inhibition Is Enhanced at Synapses Expressing FHM1 Mutant Channels. In contrast to P/Q-mediated IPSC component, the overall IPSC size did not differ between synapses expressing WT or FHM1 mutant Ca2+ channels (Fig. 4E), even when data were pooled from all four FHM1 mutants (Fig. 4F). We also examined paired-pulse depression (PPD) as a gauge of vesicle release probability (Pr), by applying pairs of stimuli 200 ms apart. PPD was not different between neurons expressing WT or FHM1 mutant channels (Table 2, which is published as supporting information on the PNAS web site), suggesting that Pr was well maintained at FHM1 mutant-expressing synapses, in line with the preservation of IPSC amplitude. All in all, expressing FHM1 mutant channels at inhibitory synapses resulted in changes of neurotransmission similar to what we observed at excitatory synapses (18): despite the consistent tilt away from P/Q-type channels and toward N-type channels, overall synaptic strength was maintained.
Could the changes at synapses expressing FHM1 mutant channels be pathogenic despite the apparent preservation of synaptic strength? One possibility is that frank alterations in synaptic strength do take place at certain synapses that regulate pain transmission, by analogy to the synapse-to-synapse variability in tottering (tg) mice (33, 34), in which α1A contains a missense mutation that decreases P/Q-type Ca2+ current (35). Alternatively, the switchover in dominant channel type could alter the susceptibility of neurotransmission to presynaptic modulation. N-type Ca2+ channels are much more responsive than P/Q-type channels to G protein modulation (36, 37); additionally, once asserted, inhibition of N-type channels is more resistant to voltage-dependent relief (38, 39). Indeed, Zhou et al. (40) have shown that transmission from parallel fibers to Purkinje neurons is more susceptible to G protein-coupled receptor modulation in tg cerebellum than in WT, presumably because of a tilt toward N-type Ca2+ channels. Finally, FHM1 mutations may also alter the sensitivity of P/Q-type channels to G protein modulation (41).
To test this idea, we compared the effect of baclofen on neurotransmission from α1A-/- synapses expressing WT, RQ, or TM α1A subunits. Baclofen binds to GABAB receptors, causing Gβγ subunits to inhibit N- and P/Q-type Ca2+ channels. At α1A-/- synapses (Fig. 5, ko group), 10 μM baclofen caused a >80% reduction of both IPSC and EPSC amplitudes that was largely reversed upon removal of the drug (data not shown). The baclofen effect was completely prevented by GABAB receptor antagonist CGP55845 (2 μM, data not shown). The inhibition of synaptic current was likely caused by baclofen acting presynaptically as indicated by previous work (42).
At α1A-/- inhibitory synapses expressing RQ or TM mutant α1A, the concentration-response curves for baclofen inhibition of IPSC were shifted strongly leftward compared with synapses expressing WT α1A (Fig. 5A). IC50 values at RQ- and TM-expressing synapses were ∼4-fold lower than WT and similar to that of α1A-/- synapses (Table 3, which is published as supporting information on the PNAS web site). Similar leftward shifts of baclofen concentration-response curves were also observed at excitatory synapses expressing RQ or TM mutant channels (Fig. 5B and Table 3). Thus, despite the apparent preservation of IPSC and EPSC amplitudes, both inhibitory and excitatory synapses grew much more responsive to neuromodulation when expressing FHM1 mutant rather than WT channels.
FHM1 Mutants Interfere with Endogenous Mouse P/Q-Type Channels in Mediating Inhibitory Synaptic Transmission. Our previous study showed that expression of FHM1 mutant channels in α1A+/+ neurons reduced the overall contribution of P/Q-type channels to excitatory synaptic transmission, suggesting a competition between mutant and α1A+/+ channels for type-preferring slots (18). Here, we tested whether similar interference took place for inhibitory synaptic transmission.
At α1A+/+ synapses expressing EGFP alone, endogenous P/Q-type channels accounted for 54 ± 7% of inhibitory synaptic transmission (Fig. 6). When the presynaptic neurons additionally expressed FHM1 channels, this proportion was reduced to 19 ± 4% for RQ (P < 0.001) or 26 ± 6% for TM (P < 0.05). The impairment of P/Q-mediated synaptic currents at inhibitory synapses was very similar to that observed at excitatory ones (18). Thus, FHM1 mutant channels were able to hamper the participation of endogenous P/Q-type channels for both excitatory and inhibitory neurotransmission. However, the overall amplitude distribution of inhibitory synaptic current was no different in α1A+/+ synapses expressing FHM1 mutants or EGFP alone (P > 0.2, data not shown).
Discussion
FHM1 Mutations Reduce the Contribution of P/Q-Type Channels to Action Potential-Induced Ca2+ Influx and Inhibitory Transmission. We have described functional consequences of FHM1 mutations on inhibitory neurotransmission and their relationship to underlying changes in P/Q-type channel activity. The experiments were motivated by knowledge that inhibitory synaptic transmission plays a critical role in controlling the gain of circuits responsible for migraine headache (see below). We found that expression of FHM1 mutant channels in place of WT strongly and consistently reduced the contribution of P/Q-type channels to inhibitory transmitter release (Fig. 4). The effects on inhibitory synaptic transmission were in close accord with biophysical observations on alterations in P/Q-type channel activity for the four FHM1 mutations first described by Ophoff et al. (4).
Each of the original FHM1 mutants produced significantly less P/Q-type channel activity than WT human α1A in whole-cell recordings, whereas the amplitudes of HVA Ca2+ currents supported by L-, N-, and R-type channels were no different (Fig. 1). The attenuation in P/Q current density at peak ranged from 50% to 80% relative to WT. In this respect our data are in good agreement with a previous study of FHM1 mutant channels expressed in cerebellar granule cells by Tottene et al. (17), who also found that FHM1 mutations decreased peak P/Q-type current. However, we did not detect a significant displacement of the midpoint voltage for voltage-dependent activation (Fig. 2 and Table 1), a notable difference because a negative-going shift in V50 has been proposed to allow FHM1 channels to carry larger Ca2+ fluxes than WT (13, 17, 20). When we tested this idea by monitoring Ca2+ currents in response to action potential-like command waveforms, simulating Ca2+ influx during neurotransmission, FHM1-expressing neurons were deficient in supporting Ca2+ entry (Fig. 3), just as found with Ba2+ currents and conventional step commands. Even if a small hyperpolarizing shift in V50 went undetected, the overall impact of FHM1 mutations on Ca2+ influx was attenuation, not potentiation. Thus, our data display a self-consistent pattern whereby FHM1 mutations produce concordant effects on conventional voltage–clamp analysis of Ba2+ currents, action potential-evoked Ca2+ influx and synaptic transmission in paired recordings (Figs. 1, 2, 3, 4 and ref. 18). Further work will be needed to determine whether the discrepancies with refs. 17 and 20 arose from the use of different splice variants of α1A or different expression systems.
Implications of Changes in P/Q-Type Ca2+ Channels for Migraine Pathophysiology. Scenarios for pain signaling must take into account both inhibitory and excitatory transmission. Stimuli that trigger migraine first activate primary afferent pain fibers that innervate the trigeminovascular system. This process in turn excites second-order projection neurons in the trigeminal nucleus caudalis (TNC), which then relay the signals to higher brain regions to generate headache (10). The efficiency of this ascending pain transmission pathway is tightly controlled at the level of TNC (43). Weakening of descending inhibition or local inhibitory feedback increases the gain of pain signaling (44). In a striking example (45), microinjection of ω-Aga-IVA into a key nucleus in the descending modulatory pathway, the periaqueductal gray, facilitates firing of TNC relay neurons, providing proof-of-principle that attenuation of P/Q-type channel activity can remove tonic descending inhibition and thereby enhance pain signaling.
Recent studies have highlighted the important influence of P/Q-type channels on inhibitory transmission per se. In tgla mice, deficiency in P/Q-type channel activity weakens GABAergic inhibition of primary afferent pain fibers and heightens behavioral sensitivity to noxious heat (46). In rat trigeminal nucleus caudalis, local application of ω-Aga-IVA increased spontaneous firing of nociceptive neurons, indicating that P/Q-type channels are important for tonic inhibitory modulation. No such effect of ω-Aga-IVA was seen with exogenous GABA present, indicating that the toxin acts by suppressing ongoing GABA release from inhibitory terminals (47). Our data complement these lines of evidence by showing that FHM1 mutations can diminish the contribution of P/Q-type channels to inhibitory neurotransmission, with the caveat that studies at exemplar synapses will need to be extended to synapses specifically implicated in migraine signaling.
One of our most striking findings was that the strength of basal inhibitory transmission can remain remarkably well preserved even with pronounced lessening of the role of P/Q-type channels. This overall constancy likely involves powerful compensatory mechanisms that make increasingly efficient use of the remaining Ca2+ influx, largely provided by N-type channels (18). Despite the preservation of basal transmission, a shift in reliance from P/Q- to N-type channels greatly increased susceptibility to presynaptic inhibition by G protein-mediated signaling (Fig. 5). Because migraine is an episodic disease, commonly triggered by emotional or physical stress, it would be reasonable to expect a heightened level of neuromodulation leading up to a migraine attack and, according to our findings, a state of weakened neurotransmission.
Supplementary Material
Acknowledgments
This work was supported by National Institutes of Health Grant NS24067 and the George D. Smith Professorship (to R.W.T.) and a Stanford Dean's Fellowship and Individual National Research Service Awards (to Y.-Q.C.).
Author contributions: Y.-Q.C. and R.W.T. designed research; Y.-Q.C. performed research; Y.-Q.C. analyzed data; and Y.-Q.C. and R.W.T. wrote the paper.
Abbreviations: FHM1, familial hemiplegic migraine type 1; APW, action potential wave-form; DIV, days in vitro; HVA, high voltage-activated; EPSC, excitatory postsynaptic current; IPSC, inhibitory postsynaptic current; ω-Aga-IVA, ω-agatoxin-IVA; WT, RQ, TM, VA, and IL, human wild-type α1A subunits and those with individual FHM1 mutation R192Q, T666M, V714A, and I1811L.
References
- 1.Ferrari, M. D. (1998) Lancet 351, 1043-1051. [DOI] [PubMed] [Google Scholar]
- 2.Goadsby, P. J., Lipton, R. B. & Ferrari, M. D. (2002) N. Engl. J. Med. 346, 257-270. [DOI] [PubMed] [Google Scholar]
- 3.Ambrosini, A. & Schoenen, J. (2003) Curr. Opin. Neurol. 16, 327-331. [DOI] [PubMed] [Google Scholar]
- 4.Ophoff, R. A., Terwindt, G. M., Vergouwe, M. N., van Eijk, R., Oefner, P. J., Hoffman, S. M., Lamerdin, J. E., Mohrenweiser, H. W., Bulman, D. E., Ferrari, M., et al. (1996) Cell 87, 543-552. [DOI] [PubMed] [Google Scholar]
- 5.Mori, Y., Friedrich, T., Kim, M. S., Mikami, A., Nakai, J., Ruth, P., Bosse, E., Hofmann, F., Flockerzi, V., Furuichi, T., et al. (1991) Nature 350, 398-402. [DOI] [PubMed] [Google Scholar]
- 6.Starr, T. V., Prystay, W. & Snutch, T. P. (1991) Proc. Natl. Acad. Sci. USA 88, 5621-5625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Dunlap, K., Luebke, J. I. & Turner, T. J. (1995) Trends Neurosci. 18, 89-98. [PubMed] [Google Scholar]
- 8.Catterall, W. A. (1998) Cell Calcium 24, 307-323. [DOI] [PubMed] [Google Scholar]
- 9.Tsien, R. W. & Wheeler, D. B. (1999) in Calcium as a Cellular Regulator, eds. Carafoli, E. & Klee, C. B. (Oxford Univ. Press, New York), pp. 171-199.
- 10.Welch, K. M. (2003) Neurology 61, S2-S8. [DOI] [PubMed] [Google Scholar]
- 11.Waeber, C. & Moskowitz, M. A. (2003) Neurology 61, S9-S20. [DOI] [PubMed] [Google Scholar]
- 12.Vanegas, H. & Schaible, H. (2000) Pain 85, 9-18. [DOI] [PubMed] [Google Scholar]
- 13.Pietrobon, D. & Striessnig, J. (2003) Nat. Rev. Neurosci. 4, 386-398. [DOI] [PubMed] [Google Scholar]
- 14.Kraus, R. L., Sinnegger, M. J., Glossmann, H., Hering, S. & Striessnig, J. (1998) J. Biol. Chem. 273, 5586-5590. [DOI] [PubMed] [Google Scholar]
- 15.Hans, M., Luvisetto, S., Williams, M. E., Spagnolo, M., Urrutia, A., Tottene, A., Brust, P. F., Johnson, E. C., Harpold, M. M., Stauderman, K. A. & Pietrobon, D. (1999) J. Neurosci. 19, 1610-1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Kraus, R. L., Sinnegger, M. J., Koschak, A., Glossmann, H., Stenirri, S., Carrera, P. & Striessnig, J. (2000) J. Biol. Chem. 275, 9239-9243. [DOI] [PubMed] [Google Scholar]
- 17.Tottene, A., Fellin, T., Pagnutti, S., Luvisetto, S., Striessnig, J., Fletcher, C. & Pietrobon, D. (2002) Proc. Natl. Acad. Sci. USA 99, 13284-13289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Cao, Y. Q., Piedras-Renteria, E. S., Smith, G. B., Chen, G., Harata, N. C. & Tsien, R. W. (2004) Neuron 43, 387-400. [DOI] [PubMed] [Google Scholar]
- 19.Mullner, C., Broos, L. A., van den Maagdenberg, A. M. & Striessnig, J. (2004) J. Biol. Chem. 279, 51844-51850. [DOI] [PubMed] [Google Scholar]
- 20.van den Maagdenberg, A. M., Pietrobon, D., Pizzorusso, T., Kaja, S., Broos, L. A., Cesetti, T., Van De Ven, R. C., Tottene, A., Van Der Kaa, J., Plomp, J. J., et al. (2004) Neuron 41, 701-710. [DOI] [PubMed] [Google Scholar]
- 21.Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D. W., Amos, C., Dobyns, W. B., Subramony, S. H., Zoghbi, H. Y. & Lee, C. C. (1997) Nat. Genet. 15, 62-69. [DOI] [PubMed] [Google Scholar]
- 22.Randall, A. & Tsien, R. W. (1995) J. Neurosci. 15, 2995-3012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Jun, K., Piedras-Renteria, E. S., Smith, S. M., Wheeler, D. B., Lee, S. B., Lee, T. G., Chin, H., Adams, M. E., Scheller, R. H., Tsien, R. W. & Shin, H. S. (1999) Proc. Natl. Acad. Sci. USA 96, 15245-15250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Fletcher, C. F., Tottene, A., Lennon, V. A., Wilson, S. M., Dubel, S. J., Paylor, R., Hosford, D. A., Tessarollo, L., McEnery, M. W., Pietrobon, D., et al. (2001) FASEB J. 15, 1288-1290. [DOI] [PubMed] [Google Scholar]
- 25.Mori, Y., Wakamori, M., Oda, S., Fletcher, C. F., Sekiguchi, N., Mori, E., Copeland, N. G., Jenkins, N. A., Matsushita, K., Matsuyama, Z. & Imoto, K. (2000) J. Neurosci. 20, 5654-5662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bayliss, D. A., Li, Y. W. & Talley, E. M. (1997) J. Neurophysiol. 77, 1362-1374. [DOI] [PubMed] [Google Scholar]
- 27.Dove, L. S., Abbott, L. C. & Griffith, W. H. (1998) J. Neurosci. 18, 7687-7699. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Lorenzon, N. M., Lutz, C. M., Frankel, W. N. & Beam, K. G. (1998) J. Neurosci. 18, 4482-4489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Lau, F. C., Abbott, L. C., Rhyu, I. J., Kim, D. S. & Chin, H. (1998) Brain Res. Mol. Brain Res. 59, 93-99. [DOI] [PubMed] [Google Scholar]
- 30.Missler, M., Zhang, W., Rohlmann, A., Kattenstroth, G., Hammer, R. E., Gottmann, K. & Sudhof, T. C. (2003) Nature 424, 939-948. [DOI] [PubMed] [Google Scholar]
- 31.Borst, J. G., Helmchen, F. & Sakmann, B. (1995) J. Physiol. (London) 489, 825-840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Takahashi, T. & Momiyama, A. (1993) Nature 366, 156-158. [DOI] [PubMed] [Google Scholar]
- 33.Caddick, S. J., Wang, C., Fletcher, C. F., Jenkins, N. A., Copeland, N. G. & Hosford, D. A. (1999) J. Neurophysiol. 81, 2066-2074. [DOI] [PubMed] [Google Scholar]
- 34.Matsushita, K., Wakamori, M., Rhyu, I. J., Arii, T., Oda, S., Mori, Y. & Imoto, K. (2002) J. Neurosci. 22, 4388-4398. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Wakamori, M., Yamazaki, K., Matsunodaira, H., Teramoto, T., Tanaka, I., Niidome, T., Sawada, K., Nishizawa, Y., Sekiguchi, N., Mori, E., et al. (1998) J. Biol. Chem. 273, 34857-34867. [DOI] [PubMed] [Google Scholar]
- 36.Currie, K. P. & Fox, A. P. (1997) J. Neurosci. 17, 4570-4579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zamponi, G. W. & Snutch, T. P. (1998) Curr. Opin. Neurobiol. 8, 351-356. [DOI] [PubMed] [Google Scholar]
- 38.Brody, D. L. & Yue, D. T. (2000) J. Neurosci. 20, 889-898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Currie, K. P. & Fox, A. P. (2002) J. Physiol. (London) 539, 419-431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zhou, Y. D., Turner, T. J. & Dunlap, K. (2003) J. Physiol. (London) 547, 497-507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Melliti, K., Grabner, M. & Seabrook, G. R. (2003) J. Physiol. (London) 546, 337-347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Luscher, C., Jan, L. Y., Stoffel, M., Malenka, R. C. & Nicoll, R. A. (1997) Neuron 19, 687-695. [DOI] [PubMed] [Google Scholar]
- 43.Woolf, C. J. & Salter, M. W. (2000) Science 288, 1765-1769. [DOI] [PubMed] [Google Scholar]
- 44.Fields, H. L. & Basbaum, A. I. (1999) in Textbook of Pain, eds. Wall, P. D. & Melzack, R. (Elsevier, London), pp. 309-329.
- 45.Knight, Y. E., Bartsch, T., Kaube, H. & Goadsby, P. J. (2002) J. Neurosci. 22, RC213: 1-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Ogasawara, M., Kurihara, T., Hu, Q. & Tanabe, T. (2001) FEBS Lett. 508, 181-186. [DOI] [PubMed] [Google Scholar]
- 47.Ebersberger, A., Portz, S., Meissner, W., Schaible, H. G. & Richter, F. (2004) Cephalalgia 24, 250-261. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.